{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:00:04Z","timestamp":1792533604343,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Multiple myeloma (MM) is typically featured by the increased levels of inflammatory cytokines in the neoplastic plasma cells (PCs) producing monoclonal immunoglobulin. PCs proliferate in the bone marrow, which will lead to extensive skeletal destruction with osteolytic lesions, osteopenia, or pathologic fractures. The diagnostic biology of MM has progressed from morphology and low-sensitivity protein analysis into multiomics-based high-throughput readout, whereas therapeutics has evolved from single active agent to potential active drug combinations underlying precision medicine. Many studies have focused on the cytokine networks that control growth, progression, and dissemination of the disease. The complexity of cytokines in MM development remains to be elucidated comprehensively. Apart from knowing that interleukin (IL)-6 is important in the pathogenesis of MM, it has been shown that IL-6 is a paracrine factor supplied by the microenvironment comprising of those cells from the myeloid compartment. Due to IL-10 was considered an immunosuppressive cytokine to promote cancer escape from immune surveillance, the role of IL-10 in this regard has been underestimated although recent advances have reported that IL-10 induces both PC proliferation and angiogenesis in MM. In addition, cumulative studies have suggested that IL-10 plays an important role in the induction of chemoresistance in many cancers; a virtual requirement of autocrine IL-10 for MM cells to escape from an IL-6-dependent proliferation loop was implicated. In this review, we summarize the available information to elucidate a new understanding of the molecular and functional roles of IL-10 in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_141_20","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T08:39:59Z","timestamp":1606984799000},"page":"257-262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma"],"prefix":"10.4103","volume":"33","author":[{"given":"Cheng-Der","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Han","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240828","doi-asserted-by":"crossref","first-page":"1852517","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: The role of cCytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm"},{"key":"R2-8-20240828","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fmed.2017.00092","article-title":"Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response","volume":"4","author":"Freire-de-Lima","year":"2017","journal-title":"Front Med (Lausanne"},{"key":"R3-8-20240828","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0140-6736(92)92795-H","article-title":"Serum interleukin 10 in early stage multiple myeloma","volume":"340","author":"Merville","year":"1992","journal-title":"Lancet"},{"key":"R4-8-20240828","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","article-title":"Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop","volume":"88","author":"Gu","year":"1996","journal-title":"Blood"},{"key":"R5-8-20240828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/bjc.2016.11","article-title":"High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma","volume":"114","author":"Wang","year":"2016","journal-title":"Br J Cancer"},{"key":"R7-8-20240828","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"key":"R8-8-20240828","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"R9-8-20240828","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/labinvest.3700552","article-title":"Achaete-scute homolog-1 linked to remodeling and preneoplasia of pulmonary epithelium","volume":"87","author":"Wang","year":"2007","journal-title":"Lab Invest"},{"key":"R10-8-20240828","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am J Hematol"},{"key":"R11-8-20240828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"R12-8-20240828","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.25657","article-title":"Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients","volume":"95","author":"Al Saleh","year":"2020","journal-title":"Am J Hematol"},{"key":"R13-8-20240828","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","article-title":"Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma","volume":"2","author":"Aljama","year":"2018","journal-title":"Blood Adv"},{"key":"R14-8-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"R15-8-20240828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","article-title":"Molecular signatures of multiple myeloma progression through single cell RNA-Seq","volume":"9","author":"Jang","year":"2019","journal-title":"Blood Cancer J"},{"key":"R16-8-20240828","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3324\/haematol.2018.211110","article-title":"Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma","volume":"104","author":"Ramakrishnan","year":"2019","journal-title":"Haematologica"},{"key":"R17-8-20240828","doi-asserted-by":"crossref","first-page":"e1007111","DOI":"10.1371\/journal.pgen.1007111","article-title":"Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk","volume":"14","author":"Waller","year":"2018","journal-title":"PLoS Genet"},{"key":"R18-8-20240828","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1470-2045(11)70143-7","article-title":"Multiple myeloma and the road to personalised medicine","volume":"12","author":"Russell","year":"2011","journal-title":"Lancet Oncol"},{"key":"R19-8-20240828","first-page":"472","article-title":"Analysis of clinical characteristics and prognostic factors of multiple myeloma: A retrospective single-center study of 787 cases","volume":"22","author":"Qian","year":"2017","journal-title":"Hematology"},{"key":"R20-8-20240828","doi-asserted-by":"crossref","first-page":"4812637","DOI":"10.1155\/2017\/4812637","article-title":"The Evolution of Prognostic Factors in Multiple Myeloma","volume":"2017","author":"Hanbali","year":"2017","journal-title":"Adv Hematol"},{"key":"R21-8-20240828","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-018-0691-4","article-title":"Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial","volume":"12","author":"Saltarella","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R22-8-20240828","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front Endocrinol (Lausanne"},{"key":"R23-8-20240828","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cyto.2014.05.017","article-title":"Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease","volume":"69","author":"Zingone","year":"2014","journal-title":"Cytokine"},{"key":"R24-8-20240828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/08820139.2016.1208219","article-title":"Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma","volume":"46","author":"Haydaroglu","year":"2017","journal-title":"Immunol Invest"},{"key":"R25-8-20240828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14735\/amko201418","article-title":"Cytokine profiles of multiple myeloma and Waldenstr\u00f6m macroglobulinemia","volume":"27","author":"Sedla\u0159\u00edkov\u00e1","year":"2014","journal-title":"Klin Onkol"},{"key":"R26-8-20240828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/cells5040043","article-title":"Role of cytokine-induced glycosylation changes in regulating cell interactions and cell signaling in inflammatory diseases and cancer","volume":"5","author":"Dewald","year":"2016","journal-title":"Cells"},{"key":"R27-8-20240828","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/BF01714900","article-title":"Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters","volume":"62","author":"Nachbaur","year":"1991","journal-title":"Ann Hematol"},{"key":"R28-8-20240828","first-page":"52","article-title":"Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma","volume":"20","author":"Filella","year":"1996","journal-title":"Cancer Detect Prev"},{"key":"R29-8-20240828","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1100\/tsw.2006.178","article-title":"Multiple myeloma and B cell lymphoma.Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model","volume":"6","author":"Kovacs","year":"2006","journal-title":"ScientificWorldJournal"},{"key":"R30-8-20240828","first-page":"1","article-title":"Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task","volume":"11","author":"Ni","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"R31-8-20240828","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cyto.2007.02.022","article-title":"Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma","volume":"37","author":"Pappa","year":"2007","journal-title":"Cytokine"},{"key":"R32-8-20240828","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00262-018-2230-0","article-title":"IL-10 inducible CD8(+) regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells","volume":"67","author":"Plaumann","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R33-8-20240828","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1084\/jem.182.6.1801","article-title":"Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells","volume":"182","author":"Chauhan","year":"1995","journal-title":"J Exp Med"},{"key":"R34-8-20240828","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/10428190290021579","article-title":"IL-10 in myeloma cells","volume":"43","author":"Otsuki","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R35-8-20240828","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1046\/j.0007-1048.2002.03336.x","article-title":"Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells","volume":"116","author":"Otsuki","year":"2002","journal-title":"Br J Haematol"},{"key":"R36-8-20240828","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hon.2322","article-title":"Polymorphism of IL-10 receptor b affects the prognosis of multiple myeloma patients treated with thalidomide and\/or bortezomib","volume":"35","author":"Kasamatsu","year":"2017","journal-title":"Hematol Oncol"},{"key":"R37-8-20240828","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0215(20010520)95:3<184::AID-IJC1031>3.0.CO;2-V","article-title":"Interleukin-10 gene promoter polymorphisms in multiple myeloma","volume":"95","author":"Zheng","year":"2001","journal-title":"Int J Cancer"},{"key":"R39-8-20240828","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"R40-8-20240828","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front Immunol"},{"key":"R41-8-20240828","doi-asserted-by":"crossref","first-page":"e1254856","DOI":"10.1080\/2162402X.2016.1254856","article-title":"PD-1\/PD-L1 inhibitors in multiple myeloma: The present and the future","volume":"5","author":"Jelinek","year":"2016","journal-title":"Oncoimmunology"},{"key":"R42-8-20240828","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J Clin Invest"},{"key":"R43-8-20240828","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"R44-8-20240828","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1158\/0008-5472.CAN-17-0740","article-title":"IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer","volume":"77","author":"Lamichhane","year":"2017","journal-title":"Cancer Res"},{"key":"R45-8-20240828","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/bjc.2017.336","article-title":"Interleukin-10-regulated tumour tolerance in non-small cell lung cancer","volume":"117","author":"Vahl","year":"2017","journal-title":"Br J Cancer"},{"key":"R46-8-20240828","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","article-title":"B-cell receptor-mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"R47-8-20240828","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2015.57","article-title":"IL10 receptor is a novel therapeutic target in DLBCLs","volume":"29","author":"B\u00e9guelin","year":"2015","journal-title":"Leukemia"},{"key":"R48-8-20240828","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"R49-8-20240828","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R50-8-20240828","first-page":"255","article-title":"Cytokines in cancer drug resistance: Cues to new therapeutic strategies","volume":"1865","author":"Jones","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"R51-8-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 expression in multiple myeloma: An alternative strategy to target the PD-1\/PD-L1 pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J Hematol Oncol"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_141_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:20Z","timestamp":1786735820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_141_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_141_20","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}